EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Central Nervous System Prophylaxis Approach in High‐Risk Diffuse Large B‐Cell Lymphoma Patients: A Retrospectively Collected, Single‐Center Cohort Analysis

Yanli Wang, Xiaolian Wen, Tao Guan, Hongwei Zhang iD, Wei'e Han, Min Bai, Xiaolan Liu, Min Zhang, Liping Su, Weihua Zhang

Cancer Medicine · 2025

DOI: 10.1002/cam4.70830 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Yanli Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Shanxi Medical University Affiliated Cancer Hospital/Shanxi Provincial Cancer Hospital/Chinese Academy of Medical Sciences Cancer Hospital Affiliated…. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Methotrexate, Central Nervous System Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Xisike Clinical Oncology Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Recent advances in the prevention of diffuse large B‐cell lymphoma (DLBCL) have considerably focused on optimal strategies for preventing its recurrence in the central nervous system (CNS) in patients. This retrospective study aimed to assess the protective efficacy of intravenous high‐dose methotrexate (HD‐MTX) regimens in newly diagnosed patients with DLBCL presenting a high risk for CNS recurrence.

Methods

A total of 136 newly diagnosed high‐risk DLBCL patients (HD‐MTX group: n = 46; non‐HD‐MTX group: n = 90) were enrolled in this retrospective study. The primary endpoints included CNS recurrence rate, progression‐free survival (PFS), overall survival (OS), and toxicity.

Results

The 2‐year CNS recurrence rates (median follow‐up period: 25.5 months; 95% confidence interval: 21.0–30.0) were 4.3% and 11.1% in the HD‐MTX and non‐HD‐MTX groups ( p = 0.337), respectively. Additionally, the 2‐year progression‐free survival (PFS) and overall survival (OS) rates were 70.7% versus 60.8% and 72.9% versus 60.8% ( p = 0.013 and p = 0.024), respectively. The subgroup analysis for PFS and OS revealed that patients classified as the National Comprehensive Cancer Network (NCCN)—International Prognostic Index (IPI) low‐ or intermediate‐risk, at a younger age, and without B symptoms demonstrated potential benefits from the HD‐MTX treatment. In total, 46 patients completed 92 cycles of HD‐MTX treatment, of which, 49 cycles were administered on day 6 of the R‐CHOP regimen, with an average delay of no more than 4 days. In contrast, the remaining 43 cycles were initiated on days 10–14 following the completion of the R‐CHOP regimen, with an average delay of 15 days. Interestingly, the incidence of hematological or non‐hematological toxicity did not differ significantly among the groups.

Conclusion

Owing to the lack of robust evidence, the role of HD‐MTX in preventing CNS recurrence could not be conclusively determined. Nevertheless, some patients could tolerate the treatment, such as younger individuals and those at NCCN‐IPI low or intermediate risk, suggesting the efficacy of intravenous HD‐MTX administration on day 6 as an optimal strategy for preventing CNS recurrence of DLBCL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseMethotrexateCentral Nervous System NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsNeoplasm Recurrence, LocalHumansFemaleMaleRetrospective StudiesMiddle AgedAgedAdultVincristineCyclophosphamideRituximabProgression-Free SurvivalAged, 80 and overPrednisoneDoxorubicinYoung Adult

Stichwörter der Autor:innen

CNS prophylaxisCNS relapsediffuse large B‐cell lymphomasystemic high‐dose methotrexate

Substanzen

MethotrexateVincristineCyclophosphamideRituximabPrednisoneDoxorubicin

Autor:innen und Institutionen

  • Shanxi Medical University Affiliated Cancer Hospital/Shanxi Provincial Cancer Hospital/Chinese Academy of Medical Sciences Cancer Hospital Affiliated Shanxi Hospital, Hematology Department, Taiyuan, China.
  • First Hospital of Shanxi Medical University, Taiyuan, China.

ORCID-Profile: Hongwei Zhang

Förderung

  • Beijing Xisike Clinical Oncology Research Foundation

Zitieren

APA

Wang, Y., Wen, X., Guan, T., Zhang, H., Han, W., Bai, M., Liu, X., Zhang, M., Su, L., & Zhang, W. (2025). Central Nervous System Prophylaxis Approach in High‐Risk Diffuse Large B‐Cell Lymphoma Patients: A Retrospectively Collected, Single‐Center Cohort Analysis. Cancer Medicine. https://doi.org/10.1002/cam4.70830

Vancouver

Wang Y, Wen X, Guan T, Zhang H, Han W, Bai M, et al. Central Nervous System Prophylaxis Approach in High‐Risk Diffuse Large B‐Cell Lymphoma Patients: A Retrospectively Collected, Single‐Center Cohort Analysis. Cancer Medicine. 2025. doi:10.1002/cam4.70830

BibTeX
@article{Wang2025,
  author = {Wang, Yanli and Wen, Xiaolian and Guan, Tao and Zhang, Hongwei and Han, Wei'e and Bai, Min and Liu, Xiaolan and Zhang, Min and Su, Liping and Zhang, Weihua},
  title = {Central Nervous System Prophylaxis Approach in High‐Risk Diffuse Large B‐Cell Lymphoma Patients: A Retrospectively Collected, Single‐Center Cohort Analysis},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.70830}
}
Kostenlos starten →